Raltegravir

Generic Name
Raltegravir
Brand Names
Isentress
Drug Type
Small Molecule
Chemical Formula
C20H21FN6O5
CAS Number
518048-05-0
Unique Ingredient Identifier
22VKV8053U
Background

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication

For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Post-exposure prophylaxis for occupational exposure to HIV therapy
Clinical Trials
Related News

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

First Posted Date
2015-07-03
Last Posted Date
2018-10-04
Lead Sponsor
Viriom
Target Recruit Count
24
Registration Number
NCT02489487
Locations
🇹🇭

Faculty of Medicine, Siriraj Hospital, Bangkok, Wanglang Road, Thailand

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation

Phase 4
Completed
Conditions
HIV
Interventions
Drug: Continuation of own regimen
Drug: Raltegravir
First Posted Date
2015-03-09
Last Posted Date
2019-01-10
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
40
Registration Number
NCT02383355

Research In Viral Eradication of HIV Reservoirs

First Posted Date
2015-01-12
Last Posted Date
2023-10-23
Lead Sponsor
Imperial College London
Target Recruit Count
60
Registration Number
NCT02336074
Locations
🇬🇧

Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom

🇬🇧

Central and North West London NHS Foundation Trust, London, United Kingdom

🇬🇧

Chelsea and Westminster NHS Foundation Trust, London, United Kingdom

and more 3 locations

A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas

Conditions
HIV Infection
Interventions
Drug: raltegravir
First Posted Date
2014-11-27
Last Posted Date
2017-05-22
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
254
Registration Number
NCT02302950
Locations
🇺🇸

Thomas Street Clinic, Houston, Texas, United States

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

First Posted Date
2014-08-18
Last Posted Date
2018-12-26
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
20
Registration Number
NCT02218320
Locations
🇺🇸

Clinical and Translational Research Center, UNC Hospitals, Chapel Hill, North Carolina, United States

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 201335 NA
Drug: Raltegravir
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02182375

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

First Posted Date
2014-05-06
Last Posted Date
2019-01-30
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
802
Registration Number
NCT02131233

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: Raltegravir
First Posted Date
2014-03-26
Last Posted Date
2016-09-13
Lead Sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Target Recruit Count
11
Registration Number
NCT02097108
Locations
🇦🇹

AKH Wien, Wien, Austria

🇦🇹

PMU Salzburg, Salzburg, Austria

🇦🇹

Ottto Wagner Spital, Wien, Austria

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

Phase 4
Completed
Conditions
HIV-1 Infection
Interventions
Drug: Efavirenz
Drug: Raltegravir
First Posted Date
2013-11-21
Last Posted Date
2019-02-25
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
107
Registration Number
NCT01989910
Locations
🇨🇳

Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei, Taiwan

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).

Phase 1
Completed
Conditions
HIV
Depression
Interventions
Drug: raltegravir
Drug: citalopram
First Posted Date
2013-11-08
Last Posted Date
2020-10-19
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
24
Registration Number
NCT01978782
Locations
🇳🇱

CRCN Radboud university medical center, Nijmegen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy